The FDA has accepted Yuflyma as an interchangeable biosimilar to adalimumab for the treatment of multiple chronic ...

The US Food and Drug Administration (FDA) has designated Celltrion’s Yuflyma (adalimumab-aaty) as an interchangeable biosimilar to AbbVie’s Humira (adalimumab). The decision allows Yuflyma to be ...

US FDA designates Celltrion’s Yuflyma as an interchangeable biosimilar to Humira: Incheon, South Korea Wednesday, April 16, 2025, 16:00 Hrs [IST] Celltrion, Inc. announced that ...

The action is intended to build upon the existing program for Medicare drug price negotiations, which was created by the ...

Coherus BioSciences, Inc.’s CHRS share price has dipped by 5.19%, which has investors questioning if this is right time to ...

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody blockbuster Humira.

has no plans to launch its already-approved Humira biosimilar in Europe. The monoclonal antibody is used to treat immune conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing ...

Suggestions that rheumatoid arthritis (RA) patients suffer more cardiovascular events when treated with Janus kinase (JAK) inhibitors compared with tumor necrosis factor (TNF) blockers or other ...

Celltrion, a global biopharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) to ...

Objectives To compare over 2 years the safety, efficacy and radiographic outcomes of subcutaneous abatacept versus adalimumab, in combination with methotrexate (MTX), in patients with rheumatoid ...

A rheumatologist discusses how her understanding of chronic pain in PsA has evolved—and how it affects her approach to ...